Objectives: Immunoglobulin-A vasculitis (IgAV) is a systemic small-vessel vasculitis in which renal involvement indicates severity of illness, and chronic kidney disease represents the most serious long-term complication. No treatment at present is specifically recommended for IgAV. Recently, rituximab (RTX) has been shown to be effective in case series of adults with IgAV. However, long term results are lacking. Aim of the study is to evaluate the effectiveness of RTX as induction therapy and maintenance of remission in adults with severe IgAV and aggressive glomerulonephritis.
Methods: This study included 12 adult-onset patients, 8 males and 4 females, mean age 45.1 years (range 19-75) with a mean follow-up duration of 33.7 months (range 6-144). All patients had a severe IgAV with biopsy proven crescentic nephritis. RTX was given for the treatment of a refractory disease or because of definite contraindications to standard therapies.
Results: Eleven patients (91.7%) achieved a clinical response at 6 months. Ten patients had a complete response (CR) while one had a partial response and was given an additional dose of RTX after 12 months for persistent proteinuria (1gr/24 hrs) despite systemic remission. He achieved a CR 6 months later. One patient was considered unresponsive to RTX and was switched to MMF. Among the 10 patients with CR, 1 needed maintenance doses of RTX every 6 months for iterative relapsing of severe purpura, 1 relapsed after 15 months and received a new induction course showing a CR again. A significant decrease in BVAS (p=0.031) and 24-hour-proteinuria (p=0.043) from RTX initiation through the last follow-up has been detected. One patient, who had a CR with RTX alone died after 6 months for therapy-unrelated cardiovascular cause.
Conclusions: RTX proved to be effective and safe for induction and maintenance of long-lasting remission in severe IgAV with aggresive renal involvement. Data also suggest that RTX can be indicated not only for refractory cases, but can be also proposed as a first line therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A case of glucocorticoid-refractory IgA vasculitis with diffuse alveolar hemorrhage: a therapeutic strategy for aberrant immunoglobulin depletion.
Mod Rheumatol Case Rep
December 2024
Department of Rheumatology, Tokyo Bay Urayasu Ichikawa Medical Center, Chiba, Japan.
Diffuse alveolar hemorrhage (DAH) is a rare and severe complication of IgA vasculitis (IgAV). Although glucocorticoids and immunosuppressive agents are used for its treatment, there is no consensus on the optimal form of treatment. We herein report the case of a 53-year-old, female patient with IgAV.
View Article and Find Full Text PDFIgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.
J Clin Med
November 2024
Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, 39011 Santander, Spain.
IgA vasculitis (IgAV), previously named as Henoch-Schönlein purpura, is the most frequent systemic vasculitis in children. In adults, IgAV is less common although it is associated with more severe disease. In fact, the frequency of glomerulonephritis (referred to as IgAV nephritis) in adults is higher than in children and tends to present more severely, with around 10-30% of those affected eventually progressing to end-stage renal disease.
View Article and Find Full Text PDFGastrointestinal manifestations and pathogenesis in childhood immunoglobulin A vasculitis.
Front Pediatr
October 2024
Department of Pediatrics, Sendai City Hospital, Sendai, Japan.
Article Synopsis
- Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, is the most common systemic vasculitis in children, affecting organs like the skin, gastrointestinal tract, joints, and kidneys.
- GI involvement in IgAV varies from mild cases to severe ones requiring surgery, and while specific endoscopic findings can aid in diagnosis, not all cases present with dermatological symptoms like purpura.
- Emerging evidence suggests that IgA enteropathy could be a variant of IgAV, as it shares similar symptoms and findings, highlighting the complex relationship between immune responses and clinical presentations in this condition.
IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristic.
Clin Exp Rheumatol
October 2024
Department of Nephrology, the Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
IgA vasculitis with nephritis (IgAVN) is closely related to IgA nephritis (IgAN) and IgA vasculitis (IgAV), but the clinical characteristics and exact pathogenesis of IgAVN remain unclear. In the present study, we have reviewed 8 clinical trials with different treatments and found that most IgAVN patients had partial recovery after treatments while few patients (26.5%) recovered completely within 6 months.
View Article and Find Full Text PDFAbdominal imaging and endoscopic characteristics of adult abdominal IgA vasculitis: a multicenter retrospective study.
Ann Med
December 2024
Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Article Synopsis
- IgA vasculitis (IgAV) is a systemic small vessel inflammation predominantly affecting adults, often presenting with gastrointestinal symptoms prior to skin purpura, complicating early diagnosis.
- A retrospective study involving 108 adult patients from three hospitals in China focused on their abdominal imaging and endoscopic results to aid in identifying IgAV early.
- Key findings included a high prevalence of acute abdominal pain, bowel wall thickening on imaging, erosions during endoscopy, with the duodenum and ileum being the most affected areas, and notable laboratory abnormalities indicating inflammation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!